Table 1 Comparison of proteomic biomarkers and current tumor markers
From: Contribution of oncoproteomics to cancer biomarker discovery
Cancer | Proteomic biomarkers | Current tumor markers | ||||
|---|---|---|---|---|---|---|
| Â | Sensitivity | Specificity | Reference | Markers | Sensitivity | Specificity |
Bladder | 80% | 90–97% | [87] | NMP22 | 31% | 95% |
Breast | 93% | 91% | [88] | CA 15-3 | 63% | 80–88% |
Colorectal | 91% | 93% | [89] | CEA | 43% | **** |
Gastric | 83% | 95% | [90] | CEA | 49% | **** |
Liver | 94% | 86% | [91] | AFP | 50% | 90% |
Lung | 87% | 80% | [92] | Cyfra21-1 | 63% | 94% |
Ovarian | 83% | 94% | [93] | CA-125 | 57% | **** |
Pancreatic | 78% | 97% | [94] | CA 19-9 | 72% | **** |
Prostate | 83% | 97% | [95] | PSA | 86% | 20–34% |